Project Details
Abstract
易普利姆瑪 ipilimumab 免疫抑制阻斷法已顯示對黑色素瘤 (melanoma) 有顯著的療效，然而仍有近半的患者對易普利姆瑪沒有感受性。本計畫將測試新穎的中孔洞二氧化矽奈米粒子 (MNPs) 對於黑色素瘤的抑制能力。此種 MNPs上修飾有類似易普利姆瑪、可抑制CTLA-4 的寡胜肽以阻斷 T 細胞的免疫檢查點、同時加載針對 ICER 的RNA干擾以維持 IL-2 刺激免疫細胞增殖的功能。Melanoma-on-chips 將與免疫細胞結合以進行 MNPs 的前臨床測試。此平台建立後也將對免疫治療感受性較弱的癌症進行驗證。此研究結果最終將進行MNPs 的GMP量產，並為臨床研究做準備。
Project IDs
Project ID:PC11104-0022
External Project ID:MOST111-2923-B182-001-MY3
External Project ID:MOST111-2923-B182-001-MY3
| Status | Finished |
|---|---|
| Effective start/end date | 01/03/22 → 03/03/23 |
Keywords
- Melanoma
- Multifunctional nanoparticle
- Inducible cAMP early repressor (ICER)
- Cytotoxic T lymphocyte associate protein-4 (CTLA-4)
- Ipilimumab
- Checkpoint blockade immunotherapy.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.